WhaleCreep

Avidity Partners Management LP 13F holdings, Q4 2024

Hedge fundSEC filingsCompare with another fundHoldings as of 2024-12-31, filed 2025-02-14

Avidity Partners Management LP disclosed 61 US equity positions worth $1.0bn in its Q4 2024 13F filing. Its largest position is DNTH at 6.2% of the reported book, followed by BSX and JANX. Versus Q3 2024 it opened 6 new positions, added to 6, reduced 46 and exited 26.

$1.0bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
61
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
6.2%
Largest position
The largest single position as a share of the reported equity book.
37.1%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
39
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q3 2024: 6 new, 6 added, 46 reduced, 26 exited

50 of 61
DNTH DIANTHUS THERAPEUTICS INCHealthcare6.2%$62.6m2.87m−1.5%reduced
BSX BOSTON SCIENTIFIC CORPHealthcare4.6%$46.0m515,000−46%reduced
JANX JANUX THERAPEUTICS INCHealthcare4.0%$39.7m741,900+32%added
NTRA NATERA INCHealthcare3.5%$35.4m223,800−60%reduced
EXK EXACT SCIENCES CORPBasic Materials3.4%$33.9m603,011+2.6%added
ISRG INTUITIVE SURGICAL INCHealthcare3.4%$33.8m64,800−56%reduced
CGON CG ONCOLOGY INCHealthcare3.1%$31.5m1.10m−34%reduced
UNH UNITEDHEALTH GROUP INCHealthcare3.0%$30.4m60,000−31%reduced
NBIX NEUROCRINE BIOSCIENCES INCHealthcare3.0%$30.1m220,400−52%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare2.9%$29.0m1.13m−18%reduced
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare2.9%$28.9m234,500−46%reduced
MIRM MIRUM PHARMACEUTICALS INCHealthcare2.7%$27.5m666,200−8.9%reduced
ACHC ACADIA HEALTHCARE COMPANY INHealthcare2.6%$26.1m658,000−33%reduced
ARVN ARVINAS INCHealthcare2.6%$26.0m1.36m−9.3%reduced
GKOS GLAUKOS CORPHealthcare2.5%$25.5m170,000−51%reduced
DXCM DEXCOM INCHealthcare2.5%$24.7m318,000+32%added
TMO THERMO FISHER SCIENTIFIC INCHealthcare2.3%$23.2m44,600−35%reduced
HUM HUMANA INCHealthcare2.3%$22.6m89,200−31%reduced
KYMR KYMERA THERAPEUTICS INCHealthcare2.0%$20.1m500,0000.0%held
AVTR AVANTOR INCHealthcare2.0%$20.0m947,000−23%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.0%$19.8m1.50m−39%reduced
CNTA CENTESSA PHARMACEUTICALS PLC–1.9%$19.5m1.17m−45%reduced
RVMD REVOLUTION MEDICINES INCHealthcare1.9%$19.5m446,200−44%reduced
XENE XENON PHARMACEUTICALS INCHealthcare1.9%$18.6m474,000−42%reduced
THC TENET HEALTHCARE CORPHealthcare1.7%$17.3m137,000−46%reduced
INSM INSMED INCHealthcare1.6%$16.1m232,800−61%reduced
AXSM AXSOME THERAPEUTICS INC.Healthcare1.6%$15.9m188,000−37%reduced
2655787D BLUEPRINT MEDICINES CORP–1.5%$15.4m176,600−44%reduced
DHR DANAHER CORP DELHealthcare1.5%$15.4m67,000−29%reduced
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.5%$14.8m352,000−53%reduced
ILMN ILLUMINA INCHealthcare1.5%$14.7m109,700−62%reduced
ABBV ABBVIE INCHealthcare1.4%$14.3m80,700−19%reduced
RCKT ROCKET PHARMACEUTICALS INCHealthcare1.3%$13.2m1.05m+41%added
BMY BRISTOL-MYERS SQUIBB COHealthcare1.2%$12.2m215,000−18%reduced
TMDX TRANSMEDICS GROUP INCHealthcare1.2%$12.0m192,400+597%added
PHAT PHATHOM PHARMACEUTICALS INCHealthcare1.1%$11.3m1.39m−23%reduced
SGRY SURGERY PARTNERS INCHealthcare1.1%$10.9m514,200−38%reduced
ORIC ORIC PHARMACEUTICALS INCHealthcare1.0%$10.2m1.27m−13%reduced
NEWAMSTERDAM PHARMA COMPANY no ticker–0.9%$9.1m354,000−60%reduced
INCY INCYTE CORPHealthcare0.9%$9.0m129,600−58%reduced
CATX PERSPECTIVE THERAPEUTICS INC–0.9%$8.6m2.69m−22%reduced
ASND ASCENDIS PHARMA A/SHealthcare0.9%$8.5m62,000−48%reduced
BHVN BIOHAVEN LTDHealthcare0.8%$8.3m222,900−52%reduced
ITCIEUR INTRA-CELLULAR THERAPIES INC–0.8%$8.1m97,000−58%reduced
IMUX IMMUNIC INCHealthcare0.8%$8.0m7.97m−3.6%reduced
CNTX CONTEXT THERAPEUTICS INC–0.8%$7.9m7.48m+0.8%added
ORKA ORUKA THERAPEUTICS INCHealthcare0.7%$6.8m352,124−55%reduced
REGN REGENERON PHARMACEUTICALSHealthcare0.6%$6.0m8,400–new
BRKR BRUKER CORPHealthcare0.4%$4.5m76,300–new
VERA VERA THERAPEUTICS INCHealthcare0.4%$4.2m100,000–new

Exited since Q3 2024

26 rows
NMRA NEUMORA THERAPEUTICS INC.1.2%$23.8m
BMRN BIOMARIN PHARMACEUTICAL INC1.1%$22.5m
ARGX ARGENX SE1.1%$20.7m
GPCR STRUCTURE THERAPEUTICS INC1.0%$18.9m
NGNE NEUROGENE INC0.9%$17.8m
430 TERNS PHARMACEUTICALS INC0.9%$17.8m
BNTX BIONTECH SE0.9%$17.2m
ZTS ZOETIS INC0.7%$13.9m
IMNM IMMUNOME INC0.7%$12.8m
APGE APOGEE THERAPEUTICS INC0.5%$9.0m
PRVA PRIVIA HEALTH GROUP INC0.4%$8.5m
HELP CYBIN INC0.4%$8.2m
ESTA ESTABLISHMENT LABS HLDGS INC0.4%$7.3m
CGEM CULLINAN THERAPEUTICS INC0.4%$7.1m
IMCR IMMUNOCORE HLDGS PLC0.3%$6.2m
SNY SANOFI SA0.3%$5.8m
EDIT EDITAS MEDICINE INC0.3%$5.0m
KEZAR LIFE SCIENCES INC no ticker0.2%$3.9m
IMVT IMMUNOVANT INC0.1%$2.8m
ANRO ALTO NEUROSCIENCE INC0.1%$2.7m
PRME PRIME MEDICINE INC0.1%$2.7m
SYRS SYROS PHARMACEUTICALS INC0.1%$2.3m
TIL INSTIL BIO INC0.10%$2.0m
PRLD PRELUDE THERAPEUTICS INC0.09%$1.8m
BLUEBIRD BIO INC no ticker0.04%$847k
CAREMAX INC no ticker0.0%$36.0k

Sector mix

  • Healthcare88.5%
  • Unclassified8.1%
  • Basic Materials3.4%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters